Page last updated: 2024-10-20

pyrazinamide and Hepatitis B Virus Infection

pyrazinamide has been researched along with Hepatitis B Virus Infection in 4 studies

pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.

Research Excerpts

ExcerptRelevanceReference
"An alternative regimen for the treatment of latent tuberculosis infection is 2 months of rifampin and pyrazinamide, but some patients have died of hepatitis associated with this therapy."7.72Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. ( Cheng, AC; Engemann, JJ; Fortenberry, ER; Hamilton, CD; Stout, JE, 2003)
"To determine whether inactive hepatitis B surface antigen (HBsAg) carriers are at a higher risk of drug-induced hepatotoxicity than control subjects during antituberculosis treatment with standard short-course regimens of isoniazid, rifampin, ethambutol, and/or pyrazinamide."3.73Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. ( Choi, MS; Chung, MP; Kim, H; Koh, WJ; Kwon, OJ; Lee, BH; Suh, GY, 2005)
"An alternative regimen for the treatment of latent tuberculosis infection is 2 months of rifampin and pyrazinamide, but some patients have died of hepatitis associated with this therapy."3.72Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. ( Cheng, AC; Engemann, JJ; Fortenberry, ER; Hamilton, CD; Stout, JE, 2003)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's3 (75.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Stout, JE1
Engemann, JJ1
Cheng, AC1
Fortenberry, ER1
Hamilton, CD1
Lee, BH1
Koh, WJ1
Choi, MS1
Suh, GY1
Chung, MP1
Kim, H1
Kwon, OJ1
Valencia Ortega, ME1
Türktaş, H1
Unsal, M1
Tülek, N1
Orüç, O1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment[NCT01724723]Phase 450 participants (Anticipated)Interventional2012-12-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

4 other studies available for pyrazinamide and Hepatitis B Virus Infection

ArticleYear
Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.
    American journal of respiratory and critical care medicine, 2003, Mar-15, Volume: 167, Issue:6

    Topics: Adolescent; Adult; Aged; Alcoholism; Antibiotics, Antitubercular; Antitubercular Agents; Chemical an

2003
Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
    Chest, 2005, Volume: 127, Issue:4

    Topics: Adult; Antitubercular Agents; Carrier State; Case-Control Studies; Chemical and Drug Induced Liver I

2005
[Medicine and television: a diagnosis history].
    Medicina clinica, 2005, Jun-11, Volume: 125, Issue:2

    Topics: Adult; Antitubercular Agents; Cholestasis, Intrahepatic; Diagnostic Errors; Hepatitis B; Hepatitis C

2005
Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis.
    Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1994, Volume: 75, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; D

1994